We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

99 hedge funds and large institutions have $357M invested in Rigel Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more capital invested

Capital invested by funds: $210M → $357M (+$146M)

41% more call options, than puts

Call options by funds: $148K | Put options by funds: $105K

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

0.09% less ownership

Funds ownership: 8.92% → 8.83% (-0.09%)

7% less funds holding

Funds holding: 107 → 99 (-8)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

Holders
99
Holders Change
-8
Holders Change %
-7.48%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
35
Reduced
30
Closed
16
Calls
$148K
Puts
$105K
Net Calls
+$43K
Net Calls Change
+$103K

Top Buyers

1
BlackRock
BlackRock
New York
+$25.8M
2
GPP
Great Point Partners
Connecticut
+$23.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.93M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.36M
5
Millennium Management
Millennium Management
New York
+$3.76M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$7.32M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.21M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.36M
4
Goldman Sachs
Goldman Sachs
New York
-$1.08M
5
CS
Credit Suisse
Switzerland
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
State of New Jersey Common Pension Fund D
26
State of New Jersey Common Pension Fund D
New Jersey
$2.81M – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.92M +$334K +13,116 +29%
PC
28
Paulson & Co
New York
$1.82M +$414K +16,230 +42%
Macquarie Group
29
Macquarie Group
Australia
$1.76M +$1.36M +53,221 New
JGC
30
J. Goldman & Co
New York
$1.64M -$731K -28,700 -37%
Deutsche Bank
31
Deutsche Bank
Germany
$1.57M -$312K -12,233 -21%
DCM
32
DAFNA Capital Management
California
$1.57M +$1.21M +47,348 New
TCIM
33
TIAA CREF Investment Management
New York
$1.49M -$84.8K -3,329 -7%
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$1.32M +$1.02M +40,028 New
NSEDCP
35
NJ State Employees Deferred Compensation Plan
New Jersey
$1.18M – – –
USAA
36
United Services Automobile Association
Texas
$1.02M -$31.4K -1,234 -4%
Morgan Stanley
37
Morgan Stanley
New York
$994K -$993K -38,954 -56%
TA
38
Teachers Advisors
New York
$922K +$166K +6,518 +31%
Charles Schwab
39
Charles Schwab
California
$888K +$169K +6,640 +33%
CS
40
Credit Suisse
Switzerland
$816K -$1.03M -40,331 -62%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$803K +$93K +3,650 +18%
Connor, Clark & Lunn Investment Management (CC&L)
42
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$704K -$47.1K -1,849 -8%
NFA
43
Nationwide Fund Advisors
Ohio
$683K -$311K -12,198 -37%
Goldman Sachs
44
Goldman Sachs
New York
$632K -$1.08M -42,481 -69%
Citadel Advisors
45
Citadel Advisors
Florida
$563K -$7.32M -287,274 -94%
TI
46
Telemetry Investments
New York
$563K +$46.7K +1,831 +12%
BCM
47
Bridgeway Capital Management
Texas
$522K – – –
Hudson Bay Capital Management
48
Hudson Bay Capital Management
Connecticut
$497K +$382K +15,000 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$478K +$88.9K +3,490 +32%
HCM
50
Highbridge Capital Management
New York
$463K -$54.6K -2,144 -13%
1
2
3 4 5

RIGL Hedge Fund Activity: Q1 2017 in Review

99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2017, worth a combined $357M — up 70% from $210M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RIGL and 14 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 35 added.

The largest buyer was BlackRock, adding an estimated $25.8M. The largest seller was Citadel Advisors, cutting an estimated $7.32M.

  • 99 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2017, down from 107 in Q4 2016.
  • Funds reported $357M of Rigel Pharmaceuticals stock for Q1 2017, up 70% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q1 2017 and 16 closed out, a net change of -2 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $25.8M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2017 was Citadel Advisors, an estimated $7.32M sold.

Based on aggregated 13F filings for Q1 2017.